WSTAM
LKFT

Wilbanks Smith & Thomas Asset Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10
Closed -$1K – 724
2018
Q3 		$1K Buy
+10
New +$1.06K ﹤0.01% 1515

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's LKFT Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2018, closing a stake of 10 shares — an estimated $1K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in LKFT in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 85 funds tracked by Wall St. Rank hold LKFT as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 10 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2018, an estimated $1K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $1K in Q3 2018.
  • 85 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.